Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04165330
Recruitment Status : Recruiting
First Posted : November 15, 2019
Last Update Posted : November 19, 2019
Advenchen Laboratories, LLC
Information provided by (Responsible Party):
Sarcoma Oncology Research Center, LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022